Streetbeat News

Analyst Ratings

KDP

Deutsche Bank analyst Steve Powers maintains a Hold rating on Keurig Dr Pepper (NASDAQ:KDP) and raises the price target from $36 to $37.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:40 pm

WELL

Scotiabank analyst Nicholas Yulico has maintained a Sector Outperform rating on Welltower (NYSE:WELL) and increased the price target from $121 to $133.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:35 pm

MSTR

TD Cowen analyst Lance Vitanza maintains a Buy rating on MicroStrategy (NASDAQ:MSTR) and raises the price target from $195 to $200.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:31 pm

SEZL

Northland Capital Markets has reiterated its 'Outperform' rating on Sezzle and increased the price target from $150 to $185, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:31 pm

CEG

Wells Fargo analyst Neil Kalton has maintained an Overweight rating on Constellation Energy (NASDAQ:CEG) and raised the price target from $250 to $300.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:29 pm

WMT

Wells Fargo analyst Edward Kelly has maintained an Overweight rating on Walmart and increased the price target from $81 to $88.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:28 pm

CLBT

TD Cowen analyst Shaul Eyal maintains a Buy rating on Cellebrite DI and raises the price target from $20 to $23, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:28 pm

ENS

Roth MKM analyst Chip Moore reaffirms a Buy rating on EnerSys (NYSE:ENS) with a maintained price target of $120.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:27 pm

DECK

Wells Fargo has maintained an Equal-Weight rating on Deckers Outdoor and adjusted its price target to $165 from $1000, reflecting a 6:1 forward stock split.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:27 pm

APVO

Roth MKM analyst Jonathan Aschoff maintains a Buy rating on Aptevo Therapeutics but lowers the price target from $15 to $8.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:25 pm